Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Durvalumab and Lenvatinib in Intrahepatic Cholangiocarcinoma
NCT06859684Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by West China Hospital of Sichuan University. Started Mar 2025; status: recruiting.
02
Drugs
durvalumablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06859684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859684.